TBPH Theravance Biopharma Inc.

-0.68  -3%
Previous Close 22.8
Open 22.68
Price To Book -24.04
Market Cap 1241066998
Shares 56,106,103
Volume 26,395
Short Ratio
Av. Daily Volume 233,428

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released September 20, 2017 - primary endpoint met.
Closed Triple - IMPACT
Approved June 21, 2013.
VIBATIV (telavancin hydrochloride) for injection
Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)
Approved April 30, 2015.
Phase 3 dosing to commence early 2019.
Phase 3 data due 1H 2019.
Closed Triple - CAPTAIN
Approval announced September 19, 2017.
Closed Triple
FDA Approval announced November 9, 2018.
Phase 2b data released August 2, 2017. Primary endpoint not met.
Velusetrag (TD-5108)
Phase 2 data released June 2016
Hepatitis C virus (HCV)
Phase 3 trial discontinued following recent interim analysis.
Phase 3 first patient enrolled late February 2015. Data due 2017
Staphylococcus aureus bacteremia
Phase 3 data due in 2016
Chronic obstructive pulmonary disease (COPD
Phase 2 commencement of dosing announced November 21, 2018.
Crohn's Disease
Phase 2b/3 initiation of dosing announced March 12, 2019.
Ulcerative Colitis
Phase 1 dosing announced November 27, 2018.

Latest News

  1. Theravance Biopharma to Present at the 18th Annual Needham Healthcare Conference
  2. Why Is Theravance Bio (TBPH) Down 7.9% Since Last Earnings Report?
  3. Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
  4. Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study
  5. Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
  6. Edited Transcript of TBPH earnings conference call or presentation 26-Feb-19 10:00pm GMT
  7. See what the IHS Markit Score report has to say about Theravance Biopharma Inc.
  8. Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates
  9. Theravance Biopharma Inc (TBPH) Q4 2018 Earnings Conference Call Transcript
  10. Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
  11. Theravance Biopharma Inc to Host Earnings Call
  12. Theravance Biopharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  13. Frontier Communications' (FTR) Q4 Earnings: What's in Store?
  14. /C O R R E C T I O N -- Theravance Biopharma, Inc./
  15. Will Leasing Support SBA Communications' (SBAC) Q4 Earnings?
  16. What's in Store for Telefonica Brasil (VIV) in Q4 Earnings?
  17. Why are deep-pocketed biotechs cutting hundreds of jobs?
  18. Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension